Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Palatin Says Partner AstraZeneca To Stop Further AZD2820 Drug Development

Palatin Technologies, Inc. (PTN: Quote), a New Jersey-based Pharma company, Friday said its partner AstraZeneca will stop all further development of the obesity drug AZD2820.

AZD2820, a clinical candidate under development by AstraZeneca with Palatin, was halted following a serious adverse event in its Phase I trial, subsequently followed by AstraZeneca' decision to discontinue its development.

In addition, Palatin said it was eligible for milestone payments, subject to certain development and regulatory milestones with further payments on achievement of sales targets.

Thursday, Palatin closed at $0.64 on the NYSE market.

Click here to receive FREE breaking news email alerts for Palatin Technologie Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Here is a quick summary of the earnings reported after the bell on Nov 19. Keurig Green Mountain, Inc. (GMCR) reported net income for the fourth quarter of $141.1 million or $0.86 per share, compared to $127.0 million or $0.83 per share for the year-ago quarter. Excluding items, adjusted net... Women's apparel retailer L Brands, Inc. said Wednesday that its third quarter profit rose 43% from last year, as sales increased 7%. The company's quarterly earnings per share also came in above analysts' expectations. At the same time, the company forecasts fourth quarter earnings below analysts' current consensus estimate, but once again raised its full year earnings outlook.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.